留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

趋化因子及其受体与肿瘤血管生成

胡珊珊 钱家鸣

胡珊珊, 钱家鸣. 趋化因子及其受体与肿瘤血管生成[J]. 协和医学杂志, 2016, 7(2): 123-127. doi: 10.3969/j.issn.1674-9081.2016.02.009
引用本文: 胡珊珊, 钱家鸣. 趋化因子及其受体与肿瘤血管生成[J]. 协和医学杂志, 2016, 7(2): 123-127. doi: 10.3969/j.issn.1674-9081.2016.02.009

趋化因子及其受体与肿瘤血管生成

doi: 10.3969/j.issn.1674-9081.2016.02.009
详细信息
    通讯作者:

    钱家鸣 电话:010-69155019, E-mail:qianjiaming1957@126.com

  • 中图分类号: R730.3

  • [1] Judah F. Role of angiogenesis in tumor growth and metastasis[J]. Semin Oncol, 2002, 29(6 Suppl 16):15-18. http://www.onacademic.com/detail/journal_1000035104649510_807a.html
    [2] Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases[J]. Nature, 2000, 407:249-257. doi:  10.1038/35025220
    [3] Bonecchi R, Galliera E, Borroni EM, et al. Chemokines and chemokine receptors:an overview[J]. Front Biosci (Landmark Ed), 2009, 14:540-551. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=10.1080/10915810305073
    [4] Dimberg A. Chemokines in angiogenesis[M]//The chemokine system in experimental and clinical hematology. Springer Berlin Heidelberg, 2010: 59-80.
    [5] Singh S, Sadanandam A, Singh RK. Chemokines in tumor angiogenesis and metastasis[J]. Cancer Metastasis Rev, 2007, 26:453-467. doi:  10.1007/s10555-007-9068-9
    [6] Bosisio D, Salvi V, Gagliostro V, et al. Angiogenic and antiangiogenic chemokines[J]. Chem Immunol Allergy, 2014, 99:89-104. http://www.karger.com/?doi=10.1159/000353317
    [7] Howard OM, Ben-Baruch A, Oppenheim JJ. Chemokines:progress toward identifying molecular targets for therapeutic agents[J]. Trends Biotechnol, 1996, 14:46-51. doi:  10.1016/0167-7799(96)80920-6
    [8] Lee HJ, Song IC, Yun HJ, et al. CXC chemokines and chemokine receptors in gastric cancer:from basic findings towards therapeutic targeting[J]. World J Gastroenterol, 2014, 20:1681-1693. doi:  10.3748/wjg.v20.i7.1681
    [9] Rollins BJ. Chemokines[J]. Blood, 1997, 90:909-928. doi:  10.1182/blood.V90.3.909
    [10] Zlotnik A, Yoshie O. The chemokine superfamily revisited[J]. Immunity, 2012, 36:705-716. doi:  10.1016/j.immuni.2012.05.008
    [11] Rossi D, Zlotnik A. The biology of chemokines and their receptors[J]. Ann Rev Immunol, 2000, 18:217-242. doi:  10.1146/annurev.immunol.18.1.217
    [12] Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation[J]. Nature, 2008, 454:436-444. doi:  10.1038/nature07205
    [13] Bernardini G, Ribatti D, Spinetti G, et al. Analysis of the role of chemokines in angiogenesis[J]. J Immunol Methods, 2003, 273:83-101. doi:  10.1016/S0022-1759(02)00420-9
    [14] Zlotnik A. Chemokines and cancer[J]. Int J Cancer, 2006, 119:2026-2029. doi:  10.1002/ijc.22024
    [15] Balkwill FR. The chemokine system and cancer[J]. J Pathol, 2012, 226:148-157. doi:  10.1002/path.3029
    [16] Marinissen MJ, Gutkind JS. G-protein-coupled receptors and signaling networks:emerging paradigms[J]. Trends Pharmacol Sci, 2001, 22:368-376. doi:  10.1016/S0165-6147(00)01678-3
    [17] Burger JA, Tsukada N, Burger M, et al. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1[J]. Blood, 2000, 96:2655-2663. doi:  10.1182/blood.V96.8.2655
    [18] Teicher BA, Fricker SP. CXCL12(SDF-1)/CXCR4 pathway in cancer[J]. Clin Cancer Res, 2010, 16:2927-2931. doi:  10.1158/1078-0432.CCR-09-2329
    [19] Müller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis[J]. Nature, 2001, 410:50-56. doi:  10.1038/35065016
    [20] Zlotnik A, Burkhardt AM, Homey B. Homeostatic chemokine receptors and organ-specific metastasis[J]. Nat Rev Immunol, 2011, 11:597-606. doi:  10.1038/nri3049
    [21] Allavena P, Germano G, Marchesi F, et al. Chemokines in cancer related inflammation[J]. Exp Cell Res, 2011, 317:664-673. doi:  10.1016/j.yexcr.2010.11.013
    [22] Sperveslage J, Frank S, Heneweer C, et al. The role of chemokine receptor CCR7 and Its ligands CCL19 and CCL21 in tumor progression of pancreatic ductal adenocarcinoma[J]. Cytokine, 2013, 63:302-310. http://search.ebscohost.com/login.aspx?direct=true&db=aph&AN=89825960&site=ehost-live
    [23] Keeley EC, Mehrad B, Strieter RM. Chemokines as mediators of tumor angiogenesis and neovascularization[J]. Experiment Cell Res, 2011, 317:685-690. doi:  10.1016/j.yexcr.2010.10.020
    [24] 陈飞兰, 张华蓉, 徐承平, 等. SDF-1/CXCR4轴活化诱导人内皮祖细胞增殖, 迁移及管型形成[J].基础医学与临床, 2008, 28:428-431. http://www.cnki.com.cn/Article/CJFDTotal-JCYL200805003.htm
    [25] Romagnani P, Annunziato F, Lasagni L, et al. Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity[J]. J Clin Invest, 2001, 107:53-63. http://pubmedcentralcanada.ca/pmcc/articles/PMC198541/
    [26] Kim WJ. Cellular signaling in tissue regeneration[J]. Yonsei Med J, 2000, 41:692-703. doi:  10.3349/ymj.2000.41.6.692
    [27] Addison CL, Daniel TO, Burdick MD, et al. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity[J]. J Immunol, 2000, 165:5269-5277. doi:  10.4049/jimmunol.165.9.5269
    [28] Lai Y, Liu XH, Zeng Y, et al. Interleukin-8 induces the endothelial cell migration through the Rac1/RhoA-p38MAPK pathway[J]. Eur Rev Med Pharmacol Sci, 2012, 16:630-638. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=be9a0df1ecd18afd4726d55579cce252
    [29] Grunewald M, Avraham I, Dor Y, et al. VEGF-induced adult neovascularization:recruitment, retention, and role of accessory cells[J]. Cell, 2006, 124:175-189. doi:  10.1016/j.cell.2005.10.036
    [30] Ping Y, Yao X, Jiang J, et al. The chemokine CXCL12 and its receptor CXCR4 promote glioma stem cell-mediated VEGF production and tumour angiogenesis via PI3K/AKT signalling[J]. J Pathol, 2011, 224:344-354. doi:  10.1002/path.2908
    [31] Jouan V, Canron X, Alemany M, et al. Inhibition of in vitro angiogenesis by platelet factor-4-derived peptides and mechanism of action[J]. Blood, 1999, 94:984-993. doi:  10.1182/blood.V94.3.984.415k31_984_993
    [32] Li M, Ransohoff RM. The roles of chemokine CXCL12 in embryonic and brain tumor angiogenesis[J]. Semin Cancer Biol, 2009, 19:111-115. doi:  10.1016/j.semcancer.2008.11.001
    [33] Sparmann A, Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis[J]. Cancer Cell, 2004, 6:447-458. doi:  10.1016/j.ccr.2004.09.028
    [34] Mizukami Y, Jo WS, Duerr EM, et al. Induction of interleukin-8 preserves the angiogenic response in HIF-1α-deficient colon cancer cells[J]. Nature Med, 2005, 11:992-997. doi:  10.1038/nm1294
    [35] Matsuo Y, Ochi N, Sawai H, et al. CXCL8/IL-8 and CXCL12/SDF-1α co-operatively promote invasiveness and angiogenesis in pancreatic cancer[J]. Int J Cancer, 2009, 124:853-861. doi:  10.1002/ijc.24040
    [36] Matsuo Y, Raimondo M, Woodward TA, et al. CXC-chemokine/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer[J]. Int J Cancer, 2009, 125:1027-1037. doi:  10.1002/ijc.24383
    [37] Hattermann K, Mentlein R. An infernal trio:the chemokine CXCL12 and its receptors CXCR4 and CXCR7 in tumor biology[J]. Ann Anat, 2013, 195:103-110. doi:  10.1016/j.aanat.2012.10.013
    [38] Romain B, Hachet-Haas M, Rohr S, et al. Hypoxia differentially regulated CXCR4 and CXCR7 signaling in colon cancer[J]. Mol Cancer, 2014, 13:58. doi:  10.1186/1476-4598-13-58
    [39] Liang Z, Brooks J, Willard M, et al. CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway[J]. Biochem Biophys Res Commun, 2007, 359:716-722. doi:  10.1016/j.bbrc.2007.05.182
    [40] Maishi N, Ohga N, Hida Y, et al. CXCR7:a novel tumor endothelial marker in renal cell carcinoma[J]. Pathol Int, 2012, 62:309-317. doi:  10.1111/j.1440-1827.2012.02792.x
    [41] Gil M, Seshadri M, Komorowski MP, et al. Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases[J]. Proc Natl Acad Sci U S A, 2013, 110:E1291-E1300. doi:  10.1073/pnas.1220580110
    [42] Miao Z, Luker KE, Summers BC, et al. CXCR7(RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature[J]. Proc Natl Acad Sci U S A, 2007, 104:15735-15740. doi:  10.1073/pnas.0610444104
    [43] Liu C, Luo D, Reynolds BA, et al. Chemokine receptor CXCR3 promotes growth of glioma[J]. Carcinogenesis, 2011, 32:129-137. doi:  10.1093/carcin/bgq224
    [44] Billottet C, Quemener C, Bikfalvi A. CXCR3, a double-edged sword in tumor progression and angiogenesis[J]. Biochim Biophys Acta, 2013, 1836:287-295. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=465cbedb660d2132a3fcfc4e485efe6f
    [45] Van Raemdonck K, Gouwy M, Lepers SA, et al. CXCL4L1 and CXCL4 signaling in human lymphatic and microvascular endothelial cells and activated lymphocytes:involvement of mitogen-activated protein (MAP) kinases, Src and p70S6 kinase[J]. Angiogenesis, 2014, 17:631-640. doi:  10.1007/s10456-014-9417-6
    [46] Zhang J, Patel L, Pienta KJ. CC chemokine ligand 2(CCL2) promotes prostate cancer tumorigenesis and metastasis[J]. Cytokine Growth Factor Rev, 2010, 21:41-48. doi:  10.1016/j.cytogfr.2009.11.009
    [47] Zheng J, Yang M, Shao J, et al. Chemokine receptor CX3CR1 contributes to macrophage survival in tumor metastasis[J]. Mol Cancer, 2013, 12:141. http://europepmc.org/abstract/MED/24245985
    [48] Singh S, Sadanandam A, Nannuru KC, et al. Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis[J]. Clin Cancer Res, 2009, 15:2380-2386. doi:  10.1158/1078-0432.CCR-08-2387
    [49] Varney ML, Singh S, Li A, et al. Small molecule antagonists for CXCR2 and CXCR1 inhibit human colon cancer liver metastases[J]. Cancer Let, 2011, 300:180-188. doi:  10.1016/j.canlet.2010.10.004
    [50] Sun X, Charbonneau C, Wei L, et al. CXCR4-targeted therapy inhibits VEGF expression and chondrosarcoma angiogenesis and metastasis[J]. Mol Cancer Ther, 2013, 12:1163-1170. doi:  10.1158/1535-7163.MCT-12-1092
    [51] Wong D, Kandagatla P, Korz W, et al. Targeting CXCR4 with CTCE-9908 inhibits prostate tumor metastasis[J]. BMC Urol, 2014, 14:12. doi:  10.1186/1471-2490-14-12
    [52] Gorbachev A, Kish D, Fairchild R. Modulating CXCR3 chemokine expression in the tumor microenvironment as a therapeutic approach for skin cancers(P2074)[J]. J Immunol, 2013, 190:132.
    [53] Somovilla-Crespo B, Alfonso-Pérez M, Cuesta-Mateos C, et al. Anti-CCR7 therapy exerts a potent anti-tumor activity in a xenograft model of human mantle cell lymphoma[J]. J Hematol Oncol, 2013, 6:1-14. doi:  10.1186/1756-8722-6-1
    [54] Jin Y, Arita M, Zhang Q, et al. Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators[J]. Invest Ophthalmol Vis Sci, 2009, 50:4743-4752. doi:  10.1167/iovs.08-2462
  • 加载中
计量
  • 文章访问数:  43
  • HTML全文浏览量:  5
  • PDF下载量:  5
  • 被引次数: 0
出版历程
  • 收稿日期:  2014-06-26
  • 刊出日期:  2016-03-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!